Cryolife (NYSE:CRY) Receiving Somewhat Positive Media Coverage, Study Shows

News coverage about Cryolife (NYSE:CRY) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cryolife earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 44.5662381561634 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Cryolife (CRY) traded down $0.40 during trading hours on Friday, hitting $18.25. The company’s stock had a trading volume of 71,574 shares, compared to its average volume of 99,561. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The stock has a market capitalization of $659.56, a price-to-earnings ratio of 65.18 and a beta of 0.77. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.

CRY has been the topic of a number of recent analyst reports. Lake Street Capital raised their price target on Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $25.00 target price on shares of Cryolife in a report on Monday, October 9th. Northland Securities reaffirmed a “buy” rating and issued a $23.50 target price on shares of Cryolife in a report on Monday, November 13th. TheStreet cut Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $23.63.

In related news, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the sale, the chief accounting officer now owns 98,705 shares in the company, valued at $1,875,395. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David Ashley Lee sold 33,190 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $630,610.00. Following the completion of the sale, the chief financial officer now owns 324,339 shares of the company’s stock, valued at approximately $6,162,441. The disclosure for this sale can be found here. Insiders have sold 59,190 shares of company stock valued at $1,138,240 in the last 90 days. Company insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/03/cryolife-cry-receiving-somewhat-positive-press-coverage-study-finds.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply